DGCI gives nod to SII’s proposal to manufacture vaccine against omicron for test, analysis
SII has obtained permission and licence to manufacture SARS-CoV-2rS drug substance for examination, test and analysis.
SII has obtained permission and licence to manufacture SARS-CoV-2rS drug substance for examination, test and analysis.